FDA– tag –
-
Regenerative and Gene Therapies for Rare Diseases Achieve Key Clinical Milestones, Including iPSC for Retinitis Pigmentosa and Gene Therapy for Pediatric Hearing Loss
RegMedNet UK Overview Significant clinical milestones have been reached in regenerative and gene therapies for rare diseases. Sumitomo Pharma America has dosed the first patient in a Phase I/IIa trial of its iPSC-derived cell therapy for... -
Cultivated Meat Regulatory Complexity: FDA’s Proposed Mandatory GRAS Notification Rule Poised to Delay Market Entry
Petfood Industry USA Overview An article in Petfood Industry highlights that regulatory complexity presents a significant challenge for the market introduction of cultivated meat products. Specifically, the FDA's proposed mandatory GRAS ... -
US Federal Approval for Cultivated Meat Advances: FDA and USDA Permit Sale of Cell-Cultivated Chicken, Contributing to Reduced Environmental Impact and Enhanced Food Supply
(Facebook post) USA Overview In the U.S., federal safety approvals for cultivated meat have advanced, with the FDA and USDA permitting the sale of specific cell-cultivated chicken products. This move highlights potential benefits like re... -
Hopstem Biotech Closes ~RMB 200M Series C Funding to Accelerate Development of FDA RMAT-Designated iPSC Cell Therapy hNPC01
Insight, China's Pharmaceutical Industry China Overview Hopstem Biotechnology announced the first close of its Series C funding round, raising approximately RMB 200 million (~$40 million USD). This capital will accelerate clinical develo... -
Adaptyx Biosciences Launches ARPA-H Backed $4 Million Study: Identifying Objective Molecular Signatures of Chronic Pain with Multi-Analyte Wearable Biosensor
BioSpace America Overview Stanford spin-out Adaptyx Biosciences, in collaboration with Attune Neurosciences, has initiated a 24-month, $4 million study to identify objective molecular signatures for chronic pain. Funded by ARPA-H’s EVIDE... -
Vexev Raises $6 Million to Drive FDA Approval and US Commercialization of VxWave Robotic Vascular Imaging Platform, Total Funding Reaches $19 Million
Pulse 2.0 (via Facebook) Australia Overview Australian medical robotics firm Vexev has secured $6 million in new funding to accelerate FDA regulatory activities and US commercialization of its AI-driven robotic vascular ultrasound platfo... -
Onalabs Secures Over 9.3 Million Euros in Funding for Sweat-Based Biosensor Technology, Accelerating Market Expansion and Clinical Validation of Sports Performance and Medical Devices
Trend Hunter Spain Overview Barcelona-based deep-tech firm Onalabs, specializing in sweat-based biosensing technology, has completed a funding round exceeding 9.3 million Euros. This capital will accelerate the industrialization and mark... -
Senseonics Eversense 365 Receives FDA Approval as World’s First Year-Long Wearable CGM, Expanded Medicare Coverage to Reshape Market
Constancy Researchers America Overview Senseonics' Eversense 365 has secured FDA approval, becoming the world's first commercially available year-long implantable continuous glucose monitor (CGM). This innovation fundamentally improves p... -
iRhythm Acquires VitalConnect for $287.5 Million, Expanding Wearable Multi-Parameter Cardiac Monitoring Platform
G-MedTech America Overview iRhythm has entered a definitive agreement to acquire VitalConnect, a leader in wearable biosensor technology and ambulatory cardiac monitoring, for approximately $287.5 million. VitalConnect's FDA-cleared plat... -
Non-Invasive Optical Glucose Sensing Advances with In Vivo Raman Platform Validation for Real-World Reliability: 2026 Research Unveiled
Sweet Light Global Overview Despite extensive research and investment, non-invasive optical glucose monitoring lacks FDA-approved products, but a 2026 study validated an in vivo Raman platform in oral glucose tolerance tests, marking sig...
